NCT05467410 (OPTIMIZE) is a NA clinical trial of COG-AM in Critical Illness, sponsored by University of Washington.

Who is sponsoring NCT05467410?

NCT05467410 is sponsored by University of Washington.

What drugs are being tested in NCT05467410?

Interventions in NCT05467410: COG-AM, COG-PM.

What condition does NCT05467410 study?

NCT05467410 studies Critical Illness, Cognitive Impairment, Circadian Dysrhythmia, Intensive Care Unit Delirium, Aging, Older People.

Is NCT05467410 still recruiting?

NCT05467410 is currently active, enrolled. Last updated 4 February 2026.

Last reviewed 2026-02-04 · How we verify

NCT05467410: OPTIMIZE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimal Timing of Computerized Cognitive Training for Older Intensive Care Unit Survivors

Active, enrolled NA Last updated 4 February 2026

What this trial tests

NA trial testing COG-AM in Critical Illness in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 November 2023

Primary endpoint
2 February 2026

31 December 2026

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	15 November 2023
Primary completion	2 February 2026
Estimated completion	31 December 2026
Sites	2 locations across United States

Drugs / interventions tested

COG-AM
COG-PM

Conditions studied

Critical Illness — all drugs for Critical Illness →
Cognitive Impairment — all drugs for Cognitive Impairment →
Circadian Dysrhythmia — all drugs for Circadian Dysrhythmia →
Intensive Care Unit Delirium — all drugs for Intensive Care Unit Delirium →

Sponsor

University of Washington

Who can join

60 and older, any sex, with Critical Illness or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

More than 60% of intensive care unit (ICU) patients are adults ages 60 and older, who are at high risk for ICU-acquired cognitive impairment. After ICU discharge, ICU survivors often experience sleep disturbances and inactivity, and almost 80% of ICU patients experience disturbances in circadian rhythm, which may affect cognitive function. Understanding the optimal, chronotherapeutic timing of cognitive interventions is crucial to promote circadian realignment and cognitive function, and may improve intervention feasibility, acceptability, and efficacy. Specific Aim 1 will determine feasibility, acceptability, and preliminary effect sizes for: 1) a morning session of a computerized cognitive training intervention \[COG\]; and 2) a late afternoon/early evening session of the COG intervention; compared to 3) standard inpatient care/usual care \[UC\]. Specific Aim 2 will examine circadian rhythm parameters to determine the optimal timing of the daily COG intervention. Exploratory Aim 3 will explore if the effects of the COG intervention on cognitive function are mediated by daytime activity, and explore if selected biological and clinical factors moderate intervention effects on cognitive function.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05467410 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 4 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05467410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing